INIS
carcinomas
100%
patients
78%
levels
35%
populations
33%
tumors
33%
plasma
33%
diseases
31%
cancer
16%
doses
14%
children
14%
malignancies
14%
variations
13%
therapy
13%
monitoring
12%
steroids
12%
drugs
12%
adrenal glands
11%
values
11%
epidemiology
11%
evaluation
11%
neoplasms
11%
quality of life
11%
data
10%
netherlands
10%
concentration
9%
comparative evaluations
9%
adults
8%
metastases
8%
pediatrics
7%
hormones
7%
Keyphrases
Adrenocortical Carcinoma
92%
Mitotane
61%
Adrenal Tumor
28%
Plasma Parameters
28%
Urinary Steroid Profile
22%
Endocrine Malignancies
22%
Pharmacokinetic Model
19%
Disease Stage
15%
Benign Adrenal Tumor
15%
Individualized Dosing
14%
Prognostic Factors
14%
Personalized Dosing
13%
Counseling
12%
Netherlands
12%
Heavily Pretreated Patients
11%
Relative Survival
11%
Targeted Immunotherapy
11%
Adrenal Cortex
11%
Adrenolytic Drugs
11%
Abdominal Mass
11%
Patient Care
11%
Hormonal Assay
11%
Disease Stabilization
11%
Proliferation Index
11%
Population Pharmacokinetic Analysis
11%
Objective Response
11%
Targeted Therapy
11%
Medical Imaging
11%
Population-based
11%
Adjuvant Therapy
11%
Medicine and Dentistry
Adrenal Cortex Carcinoma
54%
Diagnosis
30%
Disease
28%
Adrenal Tumor
26%
Overall Survival
21%
Survival Rate
16%
Urinary System
15%
Neoplasm
13%
Neuroendocrine Tumor
11%
Adrenal Cortex Tumor
11%
Quality of Life
11%
Long Term Survival
11%
Endocrine Disease
11%
Epigenomics
11%
DNA Methylation
11%
Diagnostic Accuracy
11%
Adrenal Gland
11%
Relative Survival
10%
Cancer
7%
Pediatrics
7%
Prognostic Factor
6%
Malignant Neoplasm
5%
Mitotane
5%
Cancer Treatment
5%
